GlassScriptPhysician profile
Derek Jerry Jue
NPI 1679592976
$6,748.96
in general payments reported to CMS, 2019-2025
36 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $158 · 2021: $1,299 · 2022: $1,052 · 2023: $1,278 · 2024: $1,324 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,890.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,082.36 | 2019-2025 | |
| Abbvie INC. | $951.65 | 2019-2025 | |
| Lilly USA, LLC | $757.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $738.75 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $484.93 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.53 | 2019-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $390.67 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $338.93 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amgen INC. | $218.42 | 2024-2025 | Otezla, Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $200.07 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.85 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $125.31 | 2024-2025 | Veozah |
| Nestle Healthcare Nutrition INC. | $89.22 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $69.91 | 2024-2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $68.72 | 2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Jue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.